Bicycle Therapeutics in Collaboration Agreement with Genentech

By Michael Dabaie

Bicycle Therapeutics PLC said it agreed a strategic collaboration with Genentech, part of Roche, on its Bicycle-based immuno-oncology therapies.

Bicycle said it will receive a $30 million upfront payment. Upfront payment and potential discovery, development, regulatory and commercial milestones could total up to $1.7 billion, the company said.

Under the terms of the agreement, Genentech and Bicycle will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets. Bicycle will be responsible for discovery research and early pre-clinical development up to candidate selection, and Genentech will be responsible for further development and commercialization upon the selection of candidates.

None of Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

February 25, 2020 07:43 ET (12:43 GMT)

Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024